Testing the safety of WEF-001 for KRAS-mutant cancers
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial studies a new drug called WEF-001 for people with advanced cancers that have a KRAS mutation. It aims to see if the drug is safe and shrinks tumors when used alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancer types: pancreatic, colorectal, lung, ovarian, bile duct, or bladder cancer
- Your tumor has a KRAS mutation, which will be checked by a test
- Your cancer has gotten worse after at least one previous standard treatment
- You are in good enough health to be up and about (ECOG score 0 or 1)
- No active infections, serious heart problems, or untreated brain tumors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This early-stage trial tests a new drug called LT-010391 designed to target a specific genetic mutation (KRAS G12D) found in some solid tumors. It's for patients whose cancer has progressed despite standard treatments or who cannot tolerate them.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests an experimental drug called RX001 for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change (KRAS mutation) and has stopped responding to standard treatments. The goal is to see if RX001 is safe and tolerable.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Hear when a new Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.